Which virus platform fits the program?
Align tumor biology, intended route, cargo, immune mechanism, and translational constraints.
ABOUT US
Creative Biolabs Oncolytic Virotherapy
Integrated Oncolytic Virus Discovery and Development
Creative Biolabs provides integrated research and development services for oncolytic virus programs, bringing together virology, molecular engineering, tumor biology, immunology, bioanalytics, delivery, and preclinical study.
We organize each program around the decisions that determine whether an oncolytic virus concept can become a differentiated, testable, and development-ready candidate.
Who We Are
An integrated R&D partner for oncolytic virus programs
Creative Biolabs supports biotechnology, pharmaceutical, and academic teams across the oncolytic virotherapy research and preclinical development continuum. Through our OncoVirapy™ platform and complementary reverse genetics and bacterial artificial chromosome technologies, we help translate a therapeutic concept into an engineered virus candidate, an evidence-driven evaluation strategy, and a clear path to the next development decision.
Our focus is not on generic virus construction or isolated assay delivery. We build application-driven, mechanism-aware workflows that connect virus biology with the target indication, payload strategy, tumor microenvironment, route of administration, analytical requirements, and downstream development constraints.
Services can be engaged as focused modules or assembled into an integrated program from early concept assessment through preclinical and development-readiness studies.
One connected program logicFrom therapeutic hypothesis to the next evidence-based development decision.
An Interconnected Challenge
One candidate, multiple linked development decisions
An oncolytic virus integrates the functions of a replicating biological agent, a tumor-selective therapeutic platform, a local payload delivery system, and an immune-modulating intervention. We frame each program around the questions that connect these functions.
How should efficacy and control be balanced?
Connect tumor selectivity, replication, immunogenicity, payload expression, and safety.
Which evidence can distinguish a lead?
Select assays and models that reveal robust activity rather than narrow experimental performance.
Can the candidate reach and persist at the tumor?
Evaluate delivery, neutralization, formulation, biodistribution, and route feasibility together.
What supports the next investment decision?
Integrate potency, safety, manufacturability, combination rationale, and milestone criteria.
Our Integrated Capabilities
A connected development continuum
Each work package is matched to program maturity, from rapid candidate ranking to expanded analytical, delivery, safety, and development-readiness planning.
Program Strategy and Candidate Selection
Virus-platform comparison, target indication assessment, candidate screening, mechanism mapping, payload selection, biomarker planning, delivery feasibility, and early developability review.
Oncolytic Virus Design and Engineering
Attenuation, tumor-specific promoters, miRNA detargeting, capsid or envelope retargeting, immune evasion, safety switches, replication control, and armed-virus payload design.
Construction, Rescue, and Optimization
Reverse genetics, BAC-based genome manipulation, recombinant virus rescue, clone selection, expansion, identity checks, and iterative performance optimization.
In Vitro Functional and Analytical Evaluation
Infectivity, replication, cytotoxicity, selectivity, payload function, immune activation, neutralization, combination studies, and mechanism-relevant potency assays.
In Vivo Preclinical Evaluation
Model selection, efficacy, dose and schedule, biodistribution, shedding, pharmacokinetics, toxicology, histopathology, and tumor immune profiling.
Delivery, Formulation, and Combination Strategy
Local and systemic delivery, stability, neutralization protection, active retargeting, carrier concepts, and mechanism-led combination development.
Analytical, Quality, and Development-Readiness Support
CMC planning, process studies, virus banks, stability, QC strategy, infectious titer, qPCR/ddPCR, potency methods, and integrated data packages.
Technology Platforms
Engineering routes matched to candidate complexity
Platform selection is guided by genome architecture, the intended modification, comparative design needs, and the evidence required for the next program decision.
OncoVirapy™ Platform
An integrated framework connecting platform selection, engineering, construction, validation, delivery, analytics, and development readiness.
Reverse Genetics Technology
Recovery and modification of viruses from defined genetic components for precise changes and controlled comparison of candidate variants.
Bacterial Artificial Chromosome Technology
Systematic manipulation of large or complex viral genomes where conventional engineering routes are less practical.
Virus Platforms and Program Modalities
Platform breadth guided by rational selection
We compare candidate platforms using tumor-cell entry, replication biology, genome capacity, immunogenicity, neutralizing immunity, tumor access, route of administration, safety controls, model availability, analytics, and production feasibility.
AdenovirusHerpes Simplex VirusVaccinia VirusVesicular Stomatitis VirusMeasles VirusNewcastle Disease VirusReovirusCoxsackievirusMaraba VirusPoliovirusSindbis VirusSemliki Forest VirusParvovirus
Direct Oncolysis
Translate tumor-selective infection and replication into measurable lytic activity, selectivity, and candidate-ranking criteria.
Immune Activation and Remodeling
Connect local inflammation, immune recruitment, antigen release, and tumor microenvironment changes to mechanism-aware readouts.
Payload Delivery and Combination
Align cargo design, expression control, delivery route, combination sequence, and contribution-of-components studies.
How We Work
A stage-gated path built around your next decision
The program can begin with a therapeutic concept, an existing construct, a candidate panel, or a defined study question.
Define
Clarify the indication, virus backbone, mechanism, payload, route, development stage, and question the next experiment must resolve.
Plan
Connect design, construction, models, assays, controls, milestones, quality considerations, deliverables, and dependencies.
Execute
Advance through reviewable gates for design selection, rescue, identity, functional screening, lead ranking, and model qualification.
Integrate
Deliver interpreted data, candidate comparisons, risk observations, and recommendations for optimization or progression.
Why Work With Creative Biolabs
Scientific continuity across the program
Our model keeps immediate experiments connected to the wider candidate strategy while allowing the scope to remain modular.
Engineering, virology, immunology, analytics, delivery, and preclinical design operate within one program logic.
Assays and models are selected to test how the candidate is expected to work.
Workflows can accommodate multiple virus backbones, payload classes, delivery routes, and combinations.
Comparative screening and milestone gates clarify what to optimize, advance, or discontinue.
Request a focused experiment, a connected work package, or a multi-stage integrated program.
Starting materials, controls, outputs, quality considerations, and timeline factors are defined for the project.
Online Inquiry
! All products and
services
are for Research Use Only. Not For Clinical Use.